Background
Methods
Design and setting
Protocols | 87 | 8801 | 8802 | 8805 | 9101 | 9102 | 9501 – 9502 armA | 9502 armB | 2000 |
---|---|---|---|---|---|---|---|---|---|
PDN
| 2500 | 1830 | 1830 | 150 | 2030 | 1970 | 1970 | 1620 | 1910 |
VCR
| 20.5 | 9 | 12 | 9 | 12 | 12 | 12 | 15 | 18 |
DNM
| 180 | 160 | 160 | - | 120 | 120 | - | 120 | 120 |
MTX IT
| ٧ | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ |
L-ASP
| 5400 | 80000 | 80000 | - | 80000 | 80000 | 120000 | 120000 | 80000 |
6-MP
| 6000 | 29920 | 25900 | - | 5100 | 28920 | 27350 | 6710 | 6830 |
MTX IV
| 180 | 1540 | 1500 | 30 | 1488 | 1500 | 1488 | 1500 | 1500 |
CPM
| - | 2000 | 3000 | 1600 | 1000 | 3000 | 1000 | 3000 | 2500 |
DESA
| - | 189 | 249 | 300 | 249 | 249 | 261 | 297 | 409 |
6-TG
| - | 900 | 900 | - | 840 | 840 | 780 | 780 | 780 |
ARA-C
| - | 600 | 600 | 900 | 600 | 1800 | 600 | 1600 | 600-1800 |
IFO
| - | - | - | 12000 | - | - | - | - | - |
VM-26
| - | - | - | 600 | - | - | - | - | - |
ADM
| - | 60 | 120 | 150 | 120 | 120 | 120 | 120 | 60-120 |
Num. patients exposed
| 2 | 1 | 2 | 4 | 5 | 28 | 2 | 57 | 6 |
Data collection
Data analysis
Results
Total participant population | Participants males (58 pts) | Participant females (49 pts) | Non-participans males (17 pts) | Non-participans females (15 pts) | |
---|---|---|---|---|---|
Meadian age
| |||||
sT
| 5.57 (1.20 – 13.73) | 5.93 (1.31 – 12.85) | 5.15 (1.20 – 13.73) | 5.84 (1.15 – 12.74) | 5.12 (1.14 – 13.45) |
EoT
| 7.60 (3.0 – 15.98) | 7.97 (3.23 – 14.97) | 7.16 (3.0 – 15.98) | / | / |
FH
| 17.52 (14.05 – 23.98) | 17.68 (14.05 – 23.98) | 17 · 24 (14.05- 23.7) | / | / |
Height-SDS
| |||||
sT
| 0.61 ± 1.04 | 0.62 ± 1.05 | 0.60 ± 1.05 | 0.60 ± 1.02 | 0.62 ± 1.09 |
EoT
| 0.25 ± 1.08 (0.000) | 0.30 ± 1.09 (0.003) | 0.19 ± 1.09 (0.000) | / | / |
FH
| 0.18 ± 1.13 (0.000) | 0.27 ± 1.03 (0.013) | 0.07 ± 1.25 (0.000) | / | / |
Height-SDS adjusted TH
| |||||
sT
| 0.45 ± 1.22 | 0.51 ± 1.38 | 0.38 ± 1.22 | / | / |
EoT
| 0.04 ± 1.2 (0.000) | 0.18 ± 1.36 (0.043) | -0.12 ± 1.11 (0.000) | / | / |
FH
| 0.15 ± 1.20 (0.000) | 0.37 ± 1.23 | -0.13 ± 1.11 (0.022) | / | / |
BMI-SDS
| |||||
sT
| 0.15 ± 1.32 | 0.39 ± 1.30 | -0.12 ± 1.31† | 0.35 ± 1.24 | -0.09 ± 1.20 |
EoT
| 0.58 ± 1.34 (0.000) | 0.82 ± 1.29 (0.010) | 0.29 ± 1.36 (0.015) † | / | / |
FH
| 0.51 ± 1.03 (0.010) | 0.49 ± 1.09 | 0.54 ± 0.96 (0.001) | / | / |
Changes with time in height-SDS
Changes with time in BMI-SDS
Age of exposure to chemotherapy
< 4 years | ≥ 4 years | |
---|---|---|
Height SDS
| ||
sT
| 0.54 ± 1.06 | 0.67 ± 1.03 |
EoT
| 0.14 ± 1.13 (0.000) | 0.34 ± 1.05 (0.003) |
FH
| 0.08 ± 1.13 (0.001) | 0.26 ± 1.14 (0.004) |
BMI SDS
| ||
sT
| -0.03 ± 1.20 | 0.30 ± 1.40 |
EoT
| 0.48 ± 1.42 (0.005) | 0.65 ± 1.29 (0.023) |
FH
| 0.49 ± 0.97 (0.005) | 0.53 ± 1.08 |